What drove NOVN.SW stock today?

Today’s move reflected positive Phase 3 remibrutinib data and heavy active trading. Price closed **CHF126.48** with volume **2416778.00** as investors balanced trial news with short-term profit-taking.

Is NOVN.SW stock a buy on valuation?

Valuation is mixed: **PE 23.16** is below sector average while PB is elevated. Meyka AI gives a **B+ (BUY)** grade but advises reviewing pipeline risks and 12-month forecasts before buying.

What are realistic price targets for NOVN.SW stock?

Meyka scenarios: a conservative 12-month target near **CHF120.00**, base around **CHF127.28**, and a bullish 3–5 year target **CHF140.37**. Forecasts are model-based and not guarantees.

When is Novartis next reporting earnings?

Novartis has scheduled its next earnings announcement for **2026-04-28**. That report should clarify revenue trends and margin outlook, affecting NOVN.SW stock direction.

CH Stocks

NOVN.SW Novartis (SIX) closed CHF126.48 19 Feb 2026: remibrutinib supports outlook

ByHuzaifa Zahoor February 20, 2026February 20, 2026

The NOVN.SW stock closed at CHF126.48 on 19 Feb 2026, down 1.48% on the day as investors weighed positive late-stage data for remibrutinib against short-term profit-taking. Trading volume totaled 2416778.00 shares, slightly below the 3-month average. Novartis AG (NOVN.SW) remains a market leader on the SIX in healthcare thanks to strong cash flow, a PE of 23.16, and a dividend yield near 2.73%, which frames today’s activity for active traders and longer-term investors.